Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 28, 2025 17:19 ET | Source: Cascade Prodrug Inc.

Cascade Prodrug Inc. Appoints Industry Veterans Manuel (Manny) Litchman and Andres Gutierrez to Board of Directors

EUGENE, Ore., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Cascade Prodrug, Inc. (“Cascade”), a biotechnology company focused on advancing novel Hypoxia Activated Therapies in oncology, today announced the...
August 15, 2024 13:38 ET | Source: Global Down Syndrome Foundation

Groundbreaking Crnic Institute Study Discovers Differences in Oxygen Physiology in People with Down Syndrome

Denver, Aug. 15, 2024 (GLOBE NEWSWIRE) -- The Global Down Syndrome Foundation (GLOBAL) is proud to support a groundbreaking new study published in Cell Reports by researchers from its partner and...
October 24, 2023 09:00 ET | Source: Cascade Prodrug Inc.

Cascade Announces Poster Presentation at Society for Immunotherapy of Cancer (SITC) Annual Meeting

Cascade Announces Poster Presentation at Society for Immunotherapy of Cancer (SITC) Annual Meeting
September 14, 2023 09:41 ET | Source: BIOXYTRAN, INC.

Bioxytran Announces Broad Spectrum Antiviral Activity Highlighted in ProLectin-M

BOSTON, MASSACHUSETTS, Sept. 14, 2023 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (BIXT), (the “Company”), a clinical stage biotechnology company developing oral drugs to treat COVID-19 and other viral...
April 10, 2023 13:00 ET | Source: DelveInsight Business Research LLP

Hypoxia Market Growing Significantly, Assesses DelveInsight | Teclison Ltd., Merck, Eli Lilly and Company, Reven Pharmaceuticals, Biogen Expected to Boost Hypoxia Market

New York, USA, April 10, 2023 (GLOBE NEWSWIRE) -- Hypoxia Market Growing Significantly| Teclison Ltd., Merck, Eli Lilly and Company, Reven Pharmaceuticals, Biogen Expected to Boost Hypoxia Market ...
December 20, 2021 07:02 ET | Source: Diffusion Pharmaceuticals Inc.

Diffusion Pharmaceuticals to Present at H.C. Wainwright BioConnect, Participate in Biotech Showcase and Bio Partnering at JPM during “J.P. Morgan Week 2022”

CHARLOTTESVILLE, Va., Dec. 20, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), a biopharmaceutical company developing novel therapies that...
December 16, 2021 08:59 ET | Source: Diffusion Pharmaceuticals Inc.

Diffusion Pharmaceuticals Doses First Patients in ILD-DLCO Trial

CHARLOTTESVILLE, Va., Dec. 16, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), a biopharmaceutical company developing novel therapies that...
December 01, 2021 07:02 ET | Source: Diffusion Pharmaceuticals Inc.

Diffusion Pharmaceuticals Announces Issuance of U.S. Patent 11,185,523

CHARLOTTESVILLE, Va., Dec. 01, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), a biopharmaceutical company developing novel therapies that...
November 22, 2021 07:02 ET | Source: Diffusion Pharmaceuticals Inc.

Diffusion Pharmaceuticals Doses First Participants in Altitude Trial

CHARLOTTESVILLE, Va., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), a biopharmaceutical company developing novel therapies that...
November 10, 2021 07:02 ET | Source: Diffusion Pharmaceuticals Inc.

Diffusion Pharmaceuticals Reports Third Quarter Financial Results and Provides Business Update

Announces Intent to Develop TSC to Treat Hypoxic TumorsAltitude Trial Expected to Commence in November 2021ILD-DLCO Trial Expected to Commence in Late December 2021 CHARLOTTESVILLE, Va., Nov. ...